Rekvina Laboratories share news and announcements
BSE: 526075Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹58.25.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹62 Cr4,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- −139.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,921
Rekvina Laboratories share news and announcements
398 announcements, routine notices left out, newest first. Page 3 of 8.
Sep 2024
2 Sep · Board meeting
1 Sep · Management
Aug 2024
30 Aug · Board meeting
Meeting on 2 Sep 2024: annual general meeting14 Aug · Meeting
14 Aug · Meeting
14 Aug · Meeting
12 Aug · Meeting
12 Aug · Meeting
12 Aug · Meeting
8 Aug · Intimation Of Adjourned AGM_2020-21
8 Aug · Intimation Of Adjourned AGM_2018-19
Jul 2024
29 Jul · Board meeting
19 Jul · Board meeting
Meeting on 29 Jul 2024: quarterly results15 Jul · Reg. 34 (1) Annual Report.
10 Jul · Board meeting
Meeting on 10 Jul 2024: annual general meeting and audited results10 Jul · Board meeting
Jun 2024
1 Jun · Non-Applicability Of Regulation 23 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended On 31St March, 2024
May 2024
29 May · Postponement Of Board Meeting
22 May · Management
21 May · Board meeting
Meeting on 29 May 2024: audited results
Apr 2024
27 Apr · Certificate Under Regulation 7(3) Of SEBI (LODR) Regulation 2015.
27 Apr · PCS Certificate Under Regulation 40(10)
Mar 2024
Feb 2024